iiinova — where your digital self keeps evolving

Giuseppe Tarantino, PhD

@giuseppetara.bsky.social

Instructor in Medicine at @DanaFarber @harvardmed @broadinstitute | PhD in Oncology at University of Bologna | visiting scientist @wharton

Posts Replies Media

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 20/04/2026

So well deserved! truly inspiring work in cancer research. Congrats Eli! #AACR26

010

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 13/01/2025

I'm running the Chicago Marathon with Crohn’s & Colitis Foundation Team Challenge to support those affected by Crohn's & Colitis. Join me in making a difference—every donation brings us closer to better treatments and a cure! 🏃‍♂️💙 Donate here: teamchallenge.crohnscolitisfoundation.org/index.cfm?fu...

teamchallenge.crohnscolitisfoundation.org

I'm fundraising for IBD cures!

I am participating in the 2025 Bank of America Chicago Marathon and raising funds for the Crohn’s & Colitis Foundation. With every mile, I hope to further their mission of finding cures for Crohn's di...

010

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 17/12/2024

In this review we summarizes recent advancements in melanoma immunotherapy with an emphasis on key tumor-intrinsic and -extrinsic mechanisms driving resistance. #melanoma #immunotherapy #Resistance link.springer.com/article/10.1...

link.springer.com

Overcoming Resistance Mechanisms to Melanoma Immunotherapy - American Journal of Clinical Dermatology

The advent of immune checkpoint inhibition has revolutionized treatment of advanced melanoma. While most patients derive survival benefit from established immunotherapies, notably monoclonal antibodie...

020

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

1/10🚨 New Findings Alert! 🚨 Discover how genomic heterogeneity and ploidy help predict intrinsic resistance to anti-PD-1 immune checkpoint blockade (ICB) in metastatic melanoma. 🧬https://www.science.org/doi/10.1126/sciadv.adp4670 📝 Key takeaways from our latest study: 🧵👇

131